NCT07585968招募中不适用
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia
Medtronic Cardiac Ablation Solutions6 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2026年8月17日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 260
- 试验地点
- 6
研究概览
简要总结
Sphere VT is a prospective, multi-center, single-arm, unblinded pivotal clinical study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia (MMVT) due to prior myocardial infarction (MI) will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior myocardial infarction (MI).
- •At least one episode of sustained (continuous for >30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.
- •Recurrence of sustained ventricular tachycardia despite Class I or III antiarrhythmic drug therapy or ICD intervention.
- •Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 2 months prior to the ablation procedure.
- •Age 18 through 85 years old.
- •Willing and able to provide informed consent.
- •Willing and able to comply with all pre-, post-, and follow-up testing requirements.
排除标准
- •Incessant VT necessitating hemodynamic support prior to the ablation procedure.
- •Unstable polymorphic VT or ventricular fibrillation (VF).
- •Idiopathic VT or VT of non-ischemic cardiomyopathy.
- •VT secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug-induced arrhythmia).
- •VT or VF thought to be from channelopathies.
- •More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.
- •Sarcoidosis.
- •Hypertrophic cardiomyopathy, except when due to an apical aneurysm.
- •Unstable angina.
- •Active myocardial ischemia.
- •Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.
- •Any percutaneous coronary intervention performed in a setting of unstable angina or acute MI (STEMI or non-STEMI) within 2 months (60 days) prior to the ablation procedure. Note: elective PCI performed during elective angiogram would be excluded only if occurring within 30 days prior to the ablation procedure.
- •Any cardiac surgery within 2 months (60 days) prior to the ablation procedure. Note: ICD lead implant/replacement falls under this exclusion, but ICD generator-only replacement does not.
- •Left ventricular ejection fraction (LVEF) <15%.
- •NYHA Class IV heart failure.
- •Decompensated heart failure.
- •Extravascular ICD (EV-ICD) or subcutaneous ICD (S-ICD)
- •Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).
- •Circulatory/ventricular assist device (VAD; surgical or percutaneous) implanted, planned or required for the procedure.
- •Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.
- •Presence of prosthetic valve in the aortic or mitral valve.
- •Patients with advanced COPD (on home oxygen).
- •Presence of intracardiac tumor or other abnormality that precludes vascular access, catheter introduction, or manipulation.
- •Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.
- •Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.
- •Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count <80,000).
- •Contraindication to anticoagulation.
- •End-stage renal disease (requiring dialysis).
- •Acute illness, active infection, or sepsis.
- •Life expectancy less than 12 months.
- •Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.
- •Body mass index >45 kg/m
- •Known ongoing drug or alcohol dependency.
- •Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
- •Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).
- •Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.
研究组 & 干预措施
Ventricular tachycardia catheter ablation
Experimental
Ablation using the Sphere-9 Catheter with the Affera Mapping and Ablation System
干预措施: Sphere-9 Catheter with the Affera Mapping and Ablation System (Device)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
不适用
Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral RegurgitationNCT07414225Beijing Anzhen Hospital400
招募中
3 期
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).NCT07265232Lantu Biopharma15
招募中
不适用
Transcatheter Arterial Embolization Using Nexsphere-F for Chronic Shoulder Pain Refractory to Conservative TreatmentNCT07336849Chung-Ang University Hosptial, Chung-Ang University College of Medicine44
尚未招募
不适用
Insertion of central line via supraclavicular subclavian vein in comparison to internal jugular veinCTRI/2024/09/073959Indra Gandhi Medical College60
尚未招募
不适用
VenusP-Valve™ System Long-term Follow-up 6-10 YearsNative Right Ventricle Outflow Tract(RVOT) DysfunctionNCT07531303Venus MedTech (HangZhou) Inc.55